FEB 27, 2019 Opens: 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Drug Discovery 2019

After a hugely successful inaugural year, LabRoots and the Drug Discovery planning committee are pleased to announce the 2nd Annual Drug Discovery Virtual Conference. LabRoots will host the online-only event February 27, 2019. The Drug Discovery planning committee has carefully planned and selected speakers that best represent the key challenges, opportunities, and issues in the current landscape.


This years event will include the following Tracks and Topics:
  • Novel Strategies for Drug Discovery
    • Natural Products
    • Phenotypic Screening
    • Organ on a Chip/3D Bioprinting
    • Second Harmonic Generation
    • DNA encoded libraries and Cryo-EM/Nanobodies
  • Effective Tools for Drug Development
    • Artificial Intelligence
    • Well designed in Vivo Studies
    • Systems based approaches
    • Immunological environment
  • Innovative Approaches in Clinical Trials
    • Combination Trials and Rational Design Combinations
    • Basket trials with Biomarkers
    • Pharmacogenomics
    • Adaptive study designs


Drug Discovery 2019 will bring together Industry leaders from around the world will join together and discuss the advancements, challenges and successes of discovery and develop new medications and therapies. Do not miss the opportunity to participate along such a diverse group of experts during this groundbreaking conference, which is free to all participants.

No crowded airports delayed flights or expensive hotel rooms, but still the look and feel of a first-rate conference with world-renowned experts.  Don't miss out on the opportunity to enjoy our Leaderboard, where you can move around the entire event, earning points for a chance to win one of LabRoots most popular t-shirts.

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2018 Drug Discovery Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (PACE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation, you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRdrug to follow the conversation!


Speakers
  • Senior Associate Scientist, Biogen
  • Associate-Professor, Pharmaceutical Sciences, Midwestern University
  • DISCOVERY Reagent & Training Lead, Companion Diagnostics (CDx) & DISCOVERY, Roche Tissue Diagnostics
  • Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford), Director Phase I Clinical Research, Director, Translational Oncology Program, Stanford University
  • Professor of the UCSF Helen Diller Family Comprehensive Cancer Center
  • University Veterinarian, Director of the Laboratory Animal Resources Center (LARC), University of Texas at San Antonio (UTSA), USA
  • Post Doctoral Research Scholar at University of California, San Francisco
  • Business Development Manager at AroCell AB
  • Founder and CEO, Insilo Medicine, Inc.

Show Resources
You May Also Like
NOV 02, 2016 06:00 AM PDT
C.E. CREDITS
NOV 02, 2016 06:00 AM PDT
The 7th annual Clinical Diagnostics & Research conference is now On Demand!  This premiere venue discusses the latest advances in clinical diagnostics, research and medicine. The con...
SEP 14, 2016 06:30 AM PDT
C.E. CREDITS
SEP 14, 2016 06:30 AM PDT
An industry leader in delivering instrument systems, reagents, and services to life science researchers,Beckman Coulter Life Sciences helps enable new discoveries in biology-based research...
NOV 08, 2017 06:00 AM PST
C.E. CREDITS
NOV 08, 2017 06:00 AM PST
LabRoots invites you to the 8th annual Clinical Diagnostics & Research free online conference! Clinical diagnostics is an ever-changing field of medicine and research, challenged wit...
NOV 11, 2015 06:00 AM PST
C.E. CREDITS
NOV 11, 2015 06:00 AM PST
Welcome to LabRoots’ 6th Annual Clinical Diagnostics & Research free online conference! The event is now available on-demand and you can attend sessions including keynotes...
FEB 22, 2017 06:00 AM PST
C.E. CREDITS
FEB 22, 2017 06:00 AM PST
Precision Medicine 2017 was a success and is now availabe On Demand!Imagine receiving a full diagnosis from a simple blood test, or the ability to tailor the perfect treatment to your ind...
MAY 28, 2014 06:00 AM PDT
C.E. CREDITS
MAY 28, 2014 06:00 AM PDT
This year will be our 5th annual Clinical Diagnostics & Research online conference. Attendees can earn free CME and CE Credits. The theme of this conference is a range of medical and clin...
Agenda
Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

Speakers

  • Matthew Flegal
    Senior Associate Scientist, Biogen
    Biography
      Matt entered the research field over 24 years ago as a lab animal technician at the TSI/Mason contract research facility. Since then, he has worked at contract facilities such as TSI and OREAD Biosafety as well as in industry at Pharmacia, Pfizer, Sanofi-Aventis, and Biogen. During that period he has performed a variety of surgical procedures including device implantation, transplants, orthopedic defect, ocular and vascular implants, cardiac surgery, and brain and spinal procedures. His experience ranges from mice and rats to non-human primates and livestock. In addition, he holds four patents for novel surgical devices and implants and has been training technicians, scientists, veterinarians, and physicians in surgical techniques and procedures for over 18 years. Outside of the surgical realm, he has been a study director, sonographer, Safety Pharmacology scientist, and manager. Currently Matt supervises a team of associates at Biogen who conduct surgical and non-surgical studies. Matt was also on the board of directors for the Academy of Surgical Research for over ten years, serving as their program chair for three of them as well as educational chair for two. Currently he is the program chairman for the New England branch of AALAS.
    • Annette Gilchrist, PhD
      Associate-Professor, Pharmaceutical Sciences, Midwestern University
      Biography
        An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she co-founded that focused on identifying modulators of G protein-coupled receptors (GPCRs) utilizing novel approaches (US Patent Numbers 6,559,128; 7,208,279; and 7,294,472). Her current research is on allosteric and functionally selective modulators of GPCRs with her primary receptors of interest being the chemokine receptor CCR1 and the recently deorphanized FFAR2. She is an International Editor for the British Journal of Clinical Pharmacology and recently served as a guest co-editor for a Frontiers in Endocrinology Bone Research themed issue on "Chemokines and Bone".
      • Mark Hellewell, PhD
        DISCOVERY Reagent & Training Lead, Companion Diagnostics (CDx) & DISCOVERY, Roche Tissue Diagnostics
      • Shivaani Kummar, MD, FACP
        Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford), Director Phase I Clinical Research, Director, Translational Oncology Program, Stanford University
        Biography
          Dr. Shivaani Kummar is a medical oncologist who specializes in early phase clinical drug development. She is Professor of Medicine and Director of the Phase I Clinical Research, Medical Oncology, and Translational Oncology Programs at Stanford University. She trained in Internal Medicine at Emory University in Atlanta, Georgia, and then pursued her fellowship training at the National Institutes of Health in Medical Oncology and Hematology. She then became Assistant Professor of Medicine at Yale Cancer Center, Yale University School of Medicine, where she developed in an interest in developmental therapeutics. She moved back to the National Cancer Institute (NCI), NIH, to build a clinical research program in novel cancer therapeutics and in 2011 became Head of Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, NCI. She subsequently moved to Stanford University in 2015 to create their early phase program in medical oncology. Her research interests focus on developing novel therapies for cancer, conducting pharmacokinetic and pharmacodynamic driven first-in-human trials. The clinical studies integrate genomics, imaging, and laboratory correlates into early phase trials. She serves on multiple national and international committees, and has widely published in high impact peer reviewed journals. She also serves as the Associate Division Chief for Medical Oncology.
        • Frank McCormick, PhD
          Professor of the UCSF Helen Diller Family Comprehensive Cancer Center
          Biography
            Frank McCormick, PhD, FRS, is Professor of the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick's group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies. Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.
          • Marcel Perret-Gentil, DVM, MS
            University Veterinarian, Director of the Laboratory Animal Resources Center (LARC), University of Texas at San Antonio (UTSA), USA
            Biography
              Dr. Perret-Gentil currently serves as University Veterinarian and Director of the Laboratory Animal Resources Center (LARC) at the University of Texas at San Antonio (UTSA). He is the Attending Veterinarian of the START Center for Cancer Care in San Antonio. His educational background includes a BS in Animal Science, DVM, residency and MS in Comparative Medicine, and fellowship in experimental/minimally invasive surgery. Past appointments have been in the US Army, Ethicon Endo-Surgery, Merck, University of Florida and Texas Tech Health Sciences Center. As of the current date, Dr. Perret-Gentil has published or contributed to 59 papers, articles and abstracts. He has presented 324 special presentations at various academic and research institutions, as well as national and international meetings. He serves as ad hoc Specialist for AAALAC International and consultant to the government, biotechnology industry and other institutions of higher education in the U.S. and abroad.
            • Khyati Shah, PhD
              Post Doctoral Research Scholar at University of California, San Francisco
              Biography
                Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
              • Martin Shaw
                Business Development Manager at AroCell AB
                Biography
                  Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson. From 1975-1992 Martin Shaw filled many technical and marketing roles at Pharmacia Diagnostics (now Thermo-Fisher). He and his coworkers developed and introduced the first commercial tests for neonatal hypothyroidism, celiac disease, and a range of novel biomarkers to monitor allergy and inflammation. Bringing testing close to the patient is important and Martin brings this experience from being Marketing Manager at Magnasense Technologies, Finland, where he introduced and promoted a novel point-of-care test system based on magnetically labelled antibodies. Martin has published several peer-reviewed articles on biomarkers and presented at many scientific congresses, including being guest speaker at the FDA.
                • Alex Zhavoronkov, PhD
                  Founder and CEO, Insilo Medicine, Inc.
                  Biography
                    Dr. Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He was the first to develop the deep-learned multi-modal predictors of age for drug and biomarker development. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he published over 120 peer-reviewed research papers and books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen's University, a master's in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
                  Sponsored By

                  For information on becoming a sponsor or exhibitor, please click here.


                  C.E. Credits

                  The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                  Committee

                  To download the Program Committee brochure here.


                  • Annette Gilchrist

                    An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she ...

                    See more See less
                  • Khyati Shah, PhD

                    Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                    See more See less
                  • Martin Shaw

                    Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...

                    See more See less
                  • Matthew Flegal, BS, SRS

                    Matt entered the research field over 24 years ago as a lab animal technician at the TSI/Mason contract research facility. Since then, he has worked at contract facilities such as TSI and OREAD Biosafety as well as in industry at Pharmacia, Pfizer, Sanofi-Aventis, and Biogen ...

                    See more See less
                  • Sid Topiol, PhD

                    Sid Topiol is the founder and CSO of 3D-2drug LLC, a collaborative research organization incubating drug discovery projects. 3D-2drug is rooted in the deployment of protein structure/function information into novel and efficient drug discovery opportunities. Sid received his B.S ...

                    See more See less
                  Help

                  General LabRoots Questions

                  For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                  Contact us

                  Virtual Events and Webinars

                  Supported Configurations

                  • Operating System Internet Explorer Firefox Chrome Safari
                    Vista IE8+ FF10+ Chrome15+
                    Windows 7 IE8+ FF10+ Chrome15+
                    Windows 8 IE10 FF10+ Chrome15+
                    Mac OS X   FF10+ Chrome15+ Safari5.1+
                  • Cookie settings: session cookies enabled
                  • Browser configuration must have JavaScript enabled
                  • Adobe Flash player 10.2 or later

                  To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                  Internet Connection

                  • A minimum of 100Kbps is recommended for audio-only events
                  • A minimum of 300Kbps is recommended for speaker on-video events

                  Computer Equipment

                  • Screen Resolution: Minimum 1024x768
                  • Video Card: 65,000 colors minimum
                  • Sound card and speakers (or headphones) for hearing webcast in full format
                  • Audio Card: 16-bit minimum
                  • RAM: 512MB of free RAM

                  Firewall Protocol

                  • HTTP on port 80 or HTTPS on port 443
                  • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                  • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                  Work-At-Home Attendees

                  • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                  For A Seamless Experience

                  When using a mobile device, FREE Mobile Apps are available:

                  - For viewing Webinars:

                  - For viewing Virtual Events

                  Attendee Guide

                  • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                  Virtual Event and Webinar Support:

                  Continuing Education (CME/CE) Support

                  Loading Comments...